TY - JOUR
T1 - Controlling silver release from antibacterial surface coatings on stainless steel for biofouling control
AU - Ranjbari, Kiarash
AU - Lee, Wey Lyn
AU - Ansari, Ali
AU - Barrios, Ana C.
AU - Sharif, Fariya
AU - Islam, Rafiqul
AU - Perreault, François
N1 - Funding Information:
This work was supported by the NASA STTR program (contracts no. 80NSSC19C0566 and 80NSSC21C0035 ) and the National Science Foundation , through the Nanosystems Engineering Research Center for Nanotechnology-Enabled Water Treatment (EEC- 1449500 ). We acknowledge the contribution of Mariana Hernandez Molina for her assistance in the silver release analysis. K.R. acknowledges the support of Masters Opportunity for Research in Engineering (MORE) program from the Ira A. Fulton Schools of Engineering and the use of the characterization facilities within the LeRoy Eyring Center at Arizona State University.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/8
Y1 - 2022/8
N2 - This study focuses on the in-situ nucleation of silver nanoparticles (AgNPs) on stainless steel (SS) to provide a localized antibacterial action for biofouling control during space missions. Since AgNPs rapidly dissolve in water, partial passivation of AgNPs was provided to slow down silver release and extend the lifetime of the antibacterial coating. Two different passivation approaches, based on the formation of low solubility silver sulfide (Ag2S) or silver bromide (AgBr) shells, were compared to identify the optimal passivation for biofouling control. Highest bacterial inactivation (up to 75%) occurred with sulfidized AgNPs as opposed to bromidized (up to 50%) NPs. The optimal passivation treatment for biofouling control was found at 10−5 M Na2S (for Ag2S) and 10−3 M NaBr (for AgBr) concentrations. Scanning Electron Microscopy (SEM) analyses confirmed the presence of AgNPs on AgBr and Ag2S-coated samples. Further investigation revealed that compared to pristine AgNPs, Ag release from both sulfidized and bromidized NPs was significantly lower (16% vs 6% or less). Overall, both sulfidized and bromidized AgNPs were effective at controlling biofilm formation; however, sulfidized NPs exhibited the maximum antibacterial activity, making it the preferable passivation strategy for AgNPs on SS surfaces.
AB - This study focuses on the in-situ nucleation of silver nanoparticles (AgNPs) on stainless steel (SS) to provide a localized antibacterial action for biofouling control during space missions. Since AgNPs rapidly dissolve in water, partial passivation of AgNPs was provided to slow down silver release and extend the lifetime of the antibacterial coating. Two different passivation approaches, based on the formation of low solubility silver sulfide (Ag2S) or silver bromide (AgBr) shells, were compared to identify the optimal passivation for biofouling control. Highest bacterial inactivation (up to 75%) occurred with sulfidized AgNPs as opposed to bromidized (up to 50%) NPs. The optimal passivation treatment for biofouling control was found at 10−5 M Na2S (for Ag2S) and 10−3 M NaBr (for AgBr) concentrations. Scanning Electron Microscopy (SEM) analyses confirmed the presence of AgNPs on AgBr and Ag2S-coated samples. Further investigation revealed that compared to pristine AgNPs, Ag release from both sulfidized and bromidized NPs was significantly lower (16% vs 6% or less). Overall, both sulfidized and bromidized AgNPs were effective at controlling biofilm formation; however, sulfidized NPs exhibited the maximum antibacterial activity, making it the preferable passivation strategy for AgNPs on SS surfaces.
KW - Biofouling
KW - Pseudomonas aeruginosa
KW - Silver nanoparticles
KW - Space
KW - Stainless steel
UR - http://www.scopus.com/inward/record.url?scp=85130080001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130080001&partnerID=8YFLogxK
U2 - 10.1016/j.colsurfb.2022.112562
DO - 10.1016/j.colsurfb.2022.112562
M3 - Article
C2 - 35594751
AN - SCOPUS:85130080001
SN - 0927-7765
VL - 216
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
M1 - 112562
ER -